Eptinezumab

Indications

Eptinezumab is used for:

Adult Dose

Migraine Indicated for preventive treatment of migraines 100 mg IV q3Months Some patients may benefit from a 300-mg IV dose q3Months Hepatic impairment No studies were conducted; hepatic or renal impairment is not expected to affect the pharmacokinetics of eptinezumab

Child Dose

Renal Dose

Renal impairment No studies were conducted; hepatic or renal impairment is not expected to affect the pharmacokinetics of eptinezumab

Administration

IV Preparation Dilute only in 100 mL 0.9% NaCl Infusion bags must be made of polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO) 100-mg dose: Withdraw 1 mL of eptinezumab; inject 1 mL content into a 100-mL bag of 0.9% NaCl 300-mg dose: Withdraw 3 mL of eptinezumab; inject 3 mL content into a 100-mL bag of 0.9% NaCl Gently invert diluted solution to mix completely; do not shake Discard unused portion remaining in vial(s) IV Administration Visually inspect product for particulate matter and discoloration before administration Administer by IV infusion only; do not give as IV push or bolus injection Use an IV infusion set with a 0.2-micron or 0.22-micron in-line or add-on sterile filter Infuse IV over ~30 minutes After infusion is complete, flush line with 20 mL of 0.9% NaCl

Contra Indications

Hypersensitivity to eptinezumab-jjmr or to any of the excipients

Precautions

Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred; if a hypersensitivity reaction occurs, consider discontinuing treatment and institute appropriate therapy

Pregnancy-Lactation

Pregnancy There are no adequate data on developmental risks associated with use in pregnant women No adverse developmental effects were observed following administration of eptinezumab-jjmr to pregnant animals at doses greater than those used clinically Clinical considerations Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy Lactation Data are not available regarding presence in human milk, effects on breastfed infants, or effects on milk production

Interactions

Adverse Effects

Side effects of Eptinezumab : 1-10% Nasopharyngitis (6-8%) Hypersensitivity (1-2%)

Mechanism of Action

Humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand; binds to CGRP ligand and blocks its binding to the receptor